TRR 209: Liver Cancer - New mechanistic and therapeutic concepts in a solid tumor model
TRR 209: Liver Cancer - New mechanistic and therapeutic concepts in a solid tumor model
批准号:
314905040
负责人:
金额:
$0.0万
依托单位国家:
德国
项目类别:
CRC/Transregios
财政年份:
2017
资助国家:
德国
项目状态:
已结题
起止时间:
2016-12-31 至 2021-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Liver cancer (LC) represents the sixth most frequent cancer disease and third most frequent cancer related cause of death with rising incidence even in industrialized countries. It comprises Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and primary liver tumors of mixed differentiation. LC represents an ideal model for solid cancer: major, well documented cancer risk factors are relevant for LC, namely chronic viral infection (Hepatitis B/C), obesity/metabolic syndrome (Non-alcoholic steatohepatitis), toxic injury (alcohol/aflatoxin) and chronic inflammation; still, little is known in regard to the oncogenic mechanism by which the established risk factors drive LC development, how lethal tumor progression takes place in its specific microenvironment, and how to improve treatment approaches accordingly. With excellent model systems available in LC, especially innovative mouse technologies and well annotated human LC cohorts, which reflect its causes and molecular changes, we can solve these questions.The SFB/TR 209 integrates and exploits this strong and exemplary model system constellation and the expertise of internationally leading LC researchers to tackle the relevant mechanistic and interventional questions in a coordinated and complementary manner. Research area A concentrates on tumorigenic mechanisms of the increasingly leading LC etiology in the Western World, Non-alcoholic steatohepatitis, and the main effector mechanism, chronic inflammation. Research area B investigates key progression mechanisms that shape the interaction between the LC cell and its environment, such as complex regulatory tumor cell mechanisms, tumor cell plasticity, and tumor-stroma interaction. Research area C concentrates on novel, bedside-bench-driven therapeutic approaches mainly addressing the stroma compartment, i. e. tumor immune response and vasculature. Model systems evaluation, biobanking, data storage and bioinformatics analyses issues are concentrated in the central INF-project providing a harmonized and sustainable approach to models, biological samples and data. The research efforts of the SFB/TR 209 are well linked to strong LC translational and clinical structures at all three partner sites. Existing efficient structures addressing the promotion of junior scientists, the compatibility of family and career, and gender issues established at all three partner sites will be used and specifically complemented by the SFB/TR 209. Built on its strong research track, complementary and cooperative research program, and linked to well established translational structures, the SFB/TR 209 gains relevant new mechanistic insights and interventional strategies that are expected to impact on other solid tumor diseases even beyond this clinically relevant model cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
CD209+巨噬细胞介导的血管瘤内皮细胞功能调控及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:陈千一
-
依托单位:
近滴线核^{209}Th的衰变性质研究
-
批准号:12365016
-
项目类别:地区科学基金项目
-
资助金额:31万元
-
批准年份:2023
-
负责人:周厚兵
-
依托单位:
PTC-209 抑制 WNT信号通路在结肠癌增殖转移分子机制的应用
-
批准号:2023JJ50297
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:周传意
-
依托单位:
近垒能区12C + 209Bi体系中集团转移的实验研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2022
-
负责人:贾会明
-
依托单位:
鼠伤寒沙门氏菌LPS core经由CD209/SphK1促进树突状细胞迁移加重炎症性肠病的机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:叶成林
-
依托单位:
噻唑类化合物PTC-209HBr靶向受体hSCARB2和衣壳蛋白VP1的抗肠道病毒71机制研究
-
批准号:82102374
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:唐崎
-
依托单位:
lncRNATtc3-209对视网膜缺血再灌注损伤小鼠RGCs 凋亡的影响及机制研究
-
批准号:2021JJ30935
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:李惠玲
-
依托单位:
CD209 通过调节巨噬细胞极化影响非酒精性脂肪性肝病发生发展的机制研究
-
批准号:LQ22H030011
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:王景骅
-
依托单位:
WYC-209下调HES1表达进而逆转胃癌化疗耐药的分子机制研究
-
批准号:LY21H160053
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:钱振渊
-
依托单位:
罗非鱼CD209介导非特异性细胞毒性细胞(NCC)杀伤活性的分子机制
-
批准号:32002426
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:黄瑜
-
依托单位: